Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- 1 June 2013
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 381 (9882), 2024-2032
- https://doi.org/10.1016/s0140-6736(13)61049-1
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Reactogenicity and Immunogenicity of an Enterovirus 71 Vaccine in Chinese Healthy Children and InfantsThe Pediatric Infectious Disease Journal, 2012
- Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and childrenHuman Vaccines & Immunotherapeutics, 2012
- Virology, epidemiology, pathogenesis, and control of enterovirus 71The Lancet Infectious Diseases, 2010
- Neural pathogenesis of enterovirus 71 infectionMicrobes and Infection, 2010
- EV71: An emerging infectious disease vaccine target in the Far East?Vaccine, 2010
- Enterovirus 71 infection: a new threat to global public health?The Lancet Neurology, 2008
- Genetic analysis of the VP1 region of Human enterovirus 71 strains isolated in Korea during 2000Archiv für die gesamte Virusforschung, 2003
- Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth diseaseThe Lancet, 1999
- An Epidemic of Enterovirus 71 Infection in TaiwanThe New England Journal of Medicine, 1999
- Neurogenic pulmonary oedema and enterovirus 71 encephalomyelitisThe Lancet, 1998